{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:23:53Z","timestamp":1791087833677,"version":"4.1.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,9]]},"DOI":"10.18632\/oncotarget.10469","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T12:19:25Z","timestamp":1467893965000},"page":"52239-52254","source":"Crossref","is-referenced-by-count":28,"title":["VPS34 regulates TSC1\/TSC2 heterodimer to mediate RheB and mTORC1\/S6K1 activation and cellular transformation"],"prefix":"10.18632","volume":"7","author":[{"given":"Nishant","family":"Mohan","sequence":"first","affiliation":[{"name":"Division of Biotechnology Review and Research I, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, 20993, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shen","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research I, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, 20993, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos","family":"Dokmanovic","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research I, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, 20993, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research I, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, 20993, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne S.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research I, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, 20993, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Jin","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research I, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, 20993, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Hall","year":"2000","journal-title":"Cell"},{"key":"2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1101\/gad.887201","article-title":"Regulation of translation initiation by FRAP\/mTOR","volume":"15","author":"Sonenberg","year":"2001","journal-title":"Genes Dev"},{"key":"3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Blenis","year":"2004","journal-title":"Mol Cell Biol"},{"key":"4","first-page":"113","volume-title":"Cell Cycle Control","author":"Gadaleta","year":"2014"},{"key":"5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cellsig.2009.01.012","article-title":"Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms","volume":"21","author":"Tee","year":"2009","journal-title":"Cellular Signaling"},{"key":"6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"Manning","year":"2008","journal-title":"Biochem J"},{"key":"7","doi-asserted-by":"crossref","first-page":"32493","DOI":"10.1074\/jbc.C300226200","article-title":"Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation- dependent manner","volume":"278","author":"Quilliam","year":"2003","journal-title":"J Biol Chem"},{"key":"8","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Guan","year":"2003","journal-title":"Genes Dev"},{"key":"9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ncb999","article-title":"Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins","volume":"5","author":"Pan","year":"2003","journal-title":"Nat Cell Biol"},{"key":"10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Guan","year":"2002","journal-title":"Nat Cell Biol"},{"key":"11","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1073\/pnas.93.17.9154","article-title":"Suppression of tumourigenicity by the wild-type tuberous sclerosis 2 () gene and its C-terminal region","volume":"93","author":"Yeung","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"12","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1038\/sj.onc.1204009","article-title":"The tuberous sclerosis-1 () gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination","volume":"19","author":"DeClue","year":"2000","journal-title":"Oncogene"},{"key":"13","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.1074\/jbc.C500451200","article-title":"TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase","volume":"281","author":"Guan","year":"2006","journal-title":"J Biol Chem"},{"key":"14","first-page":"1926","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Sonenberg","year":"2014","journal-title":"Genes Dev"},{"key":"15","doi-asserted-by":"crossref","first-page":"33076","DOI":"10.1074\/jbc.M507201200","article-title":"hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase","volume":"280","author":"Backer","year":"2005","journal-title":"J Biol Chem"},{"key":"16","doi-asserted-by":"crossref","first-page":"14238","DOI":"10.1073\/pnas.0506925102","article-title":"Amino acids mediate mTOR\/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase","volume":"102","author":"Thomas","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ceb.2007.02.019","article-title":"hVps34, an ancient player, enters a growing game: mTOR complex 1\/S6K1 signaling","volume":"19","author":"Thomas","year":"2007","journal-title":"Curr Opin Cell Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2007.04.002","article-title":"mTOR complex 1-6K1 signaling: at the crossroads of obesity, diabetes and cancer","volume":"13","author":"Thomas","year":"2007","journal-title":"Trends Mol Med"},{"key":"19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20071427","article-title":"The regulation and function of class III PI3Ks: novel roles for Vps34","volume":"410","author":"Backer","year":"2008","journal-title":"Biochem J"},{"key":"20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.cellsig.2014.02.009","article-title":"Insulin activation of vacuolar protein sorting 34 mediates localized phosphatidylinositol 3-phosphate production at lamellipodia and activation of mTOR\/S6K1","volume":"26","author":"Wu","year":"2014","journal-title":"Cell Signal"},{"key":"21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nrc1753","article-title":"Oncogenic PI3K deregulates transcription and translation","volume":"5","author":"Vogt","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Kinzler","year":"2004","journal-title":"Science"},{"key":"23","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/0008-5472.CAN-04-1170","article-title":"Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas","volume":"64","author":"Yan","year":"2004","journal-title":"Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4161\/cbt.3.8.994","article-title":"The PIK3CA gene is mutated with high frequency in human breast cancers","volume":"3","author":"Park","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"25","first-page":"1351","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"12","author":"Lightbown","year":"2008","journal-title":"Nat Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.onc.1208304","article-title":"PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas","volume":"24","author":"Lee","year":"2005","journal-title":"Oncogene"},{"key":"27","first-page":"802","article-title":"Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic","volume":"102","author":"Vogt","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"28","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1073\/pnas.0510857103","article-title":"Cancer-specific mutations in PIK3CA are oncogenic in vivo","volume":"103","author":"Vogt","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2209\/tdcpublication.50.125","article-title":"Activation of PI3K-AKT pathway in oral epithelial dysplasia and early cancer of tongue","volume":"50","author":"Yamane","year":"2009","journal-title":"Bull Tokyo Dent Coll"},{"key":"30","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1158\/0008-5472.CAN-09-2682","article-title":"pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation","volume":"70","author":"Wu","year":"2010","journal-title":"Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/35015585","article-title":"The \u03b3-subunit of the coatomer complex binds Cdc42 to mediate transformation","volume":"405","author":"Cerione","year":"2000","journal-title":"Nature"},{"key":"32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.plipres.2007.06.001","article-title":"Mechanistic similarities in docking of the FYVE and PX domains to phosphatidylinositol 3-phosphate containing membranes","volume":"46","author":"Kutateladze","year":"2007","journal-title":"Prog Lipid Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1091\/mbc.e11-12-1034","article-title":"Phosphatidylinositol 3,5-bisphosphate plays a role in the activation and subcellular localization of mechanistic target of rapamycin 1","volume":"23","author":"Saltiel","year":"2012","journal-title":"Mol Biol Cell"},{"key":"34","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","article-title":"Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2","volume":"11","author":"Thomas","year":"2003","journal-title":"Mol Cell"},{"key":"35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbrc.2008.05.062","article-title":"Elevated levels of PtdIns5P in NPM-ALK transformed cells: implication of PIKfyve","volume":"372","author":"Tronch\u00e8re","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1042\/BJ20140132","article-title":"PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1","volume":"461","author":"Wesche","year":"2014","journal-title":"Biochem J"},{"key":"37","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.bbamcr.2015.01.008","article-title":"Class III PI 3-kinase is the main source of Ptdlns3P substrate and membrane recruitment signal for PIKfyve constitutive function in podocyte endomembrane homeostasis","volume":"1853","author":"Shisheva","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/nyas.12026","article-title":"Class III PI3K Vps34: essential roles in autophagy, endocytosis, and heart and liver function","volume":"1280","author":"Zong","year":"2013","journal-title":"Ann NY Acad Sci"},{"key":"39","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1074\/jbc.275.9.6267","article-title":"The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity","volume":"275","author":"Vogt","year":"2000","journal-title":"J Biol Chem"},{"key":"40","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Sawyers","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"41","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1073\/pnas.171060098","article-title":"An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice","volume":"98","author":"Blenis","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"42","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0092-8674(03)00688-3","article-title":"Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation","volume":"114","author":"Cerione","year":"2003","journal-title":"Cell"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T10:18:32Z","timestamp":1589278712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":42,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2016,8,9]]}},"alternative-id":["10469","27409169"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10469","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}